Allogene Therapeutics ALLO Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $32M+11.8% | $28.63M-8.1% | $31.16M-22.4% | $40.16M-20.0% | $50.2M+11.6% | ||
| $14.09M+2.3% | $13.77M+0.3% | $13.74M-3.8% | $14.28M-4.7% | $14.99M-3.4% | ||
| $46.09M+8.7% | $42.4M-5.6% | $44.9M-21.0% | $56.82M-12.8% | $65.19M+7.8% | ||
| -$46.09M-8.7% | -$42.4M+5.6% | -$44.9M+21.0% | -$56.82M+12.8% | -$65.19M-7.8% | ||
| $300K-4.2% | $313K-9.0% | $344K+28.4% | $268K+78.7% | $150K+85.2% | ||
| $3.57M-2.4% | $3.66M-6.8% | $3.93M-36.5% | $6.19M+12.2% | $5.52M+82.2% | ||
| $3.49M-3.0% | $3.59M+2.7% | $3.5M-40.4% | $5.88M+7.7% | $5.46M+449% | ||
| -$42.61M-9.8% | -$38.81M+6.3% | -$41.4M+18.7% | -$50.94M+14.7% | -$59.73M+0.3% | ||
| -$0.18-5.9% | -$0.17+10.5% | -$0.19+17.4% | -$0.23+17.9% | -$0.280.0% | ||
| -$0.18-5.9% | -$0.17+10.5% | -$0.19+17.4% | -$0.23+17.9% | -$0.280.0% | ||
| 240.3M+8.9% | 220.6M-0.6% | 222M+1.4% | 218.9M+1.7% | 215.4M+10.5% | ||
| 240.3M+8.9% | 220.6M-0.6% | 222M+1.4% | 218.9M+1.7% | 215.4M+10.5% | ||
| -$43.06M-11.0% | -$38.78M+5.7% | -$41.12M+19.4% | -$51.03M+14.4% | -$59.6M+1.0% | ||
| $3.57M-2.4% | $3.66M-6.8% | $3.93M-36.5% | $6.19M+12.2% | $5.52M+82.2% | ||
| -$452K-1,429% | $34K-87.9% | $280K+418% | -$88K-167% | $132K— | ||
| $212K-14.2% | $247K+405% | -$81K-88.4% | -$43K-147% | $92K+105% | ||
| -$46.09M-8.7% | -$42.4M+5.6% | -$44.9M+21.0% | -$56.82M+12.8% | -$65.19M-7.8% | ||
| -$43.22M-9.9% | -$39.35M+5.9% | -$41.8M+22.2% | -$53.71M+13.5% | -$62.09M-8.4% | ||
| -$43.22M-9.9% | -$39.35M+5.9% | -$41.8M+22.2% | -$53.71M+13.5% | -$62.09M-8.4% | ||
| -$46.09M-8.7% | -$42.4M+5.6% | -$44.9M+21.0% | -$56.82M+12.8% | -$65.19M-7.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Allogene Therapeutics profitable?
- Allogene Therapeutics is not currently profitable: it reported a net loss of $173.8M over the trailing twelve months, a -1170863.6% net margin.
- What is Allogene Therapeutics's earnings per share?
- Allogene Therapeutics's diluted EPS over the trailing twelve months is $-0.77.
- Where does Allogene Therapeutics's income statement data come from?
- Every line is extracted from Allogene Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.